Akeso reported overall survival benefit for ivonescimab plus chemotherapy in Phase III lung cancer study. The company enrolled first patient in Phase Ib/II trial of next-generation HER3 ADC AK138D1 for advanced breast cancer. Akeso also received China approval to start Phase II trials for AK139 bispecific antibody.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07700979 |
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07631000 |
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer |
RECRUITING | PHASE2 |
| NCT07446257 |
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT06511726 |
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06187961 |
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05944224 |
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. |
RECRUITING | PHASE1/PHASE2 |
| NCT05426005 |
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
